Blockchain Registration Transaction Record

GeoVax's Dual-Antigen COVID-19 Vaccine Targets Vulnerable Immunocompromised Populations

GeoVax publishes peer-reviewed data on GEO-CM04S1, a dual-antigen COVID-19 vaccine designed for immunocompromised patients. Learn how it targets spike and nucleocapsid proteins for broader protection.

This development is crucial because immunocompromised individuals, including cancer patients, transplant recipients, and those on immunosuppressive therapies, represent a significant population at heightened risk for severe COVID-19 outcomes. First-generation vaccines, which primarily target the spike protein, often fail to elicit adequate immune responses in these vulnerable groups, leaving them unprotected. GEO-CM04S1's dual-antigen approach, targeting both spike and nucleocapsid proteins, aims to generate broader and more durable T-cell and antibody responses, potentially closing this protection gap. By addressing a critical unmet medical need, this vaccine could reduce hospitalizations and deaths among millions of high-risk patients worldwide, enhancing public health resilience and offering hope for those with compromised immune systems who have remained disproportionately affected throughout the pandemic.